Skip to content

Genetic test for *Epsilon-Cadherin* (CDH1) mutation screening via probe-based assay

Published: August 9, 2026Updated: August 16, 2026

This test checks for mutations in the *Epsilon-Cadherin* gene, which may be linked to certain inherited cancers or syndromes. Results help guide personalized cancer prevention or monitoring plans.

Quick summary

["Assesses genetic risk for cancer-related conditions through a specific gene mutation."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
87372-9
Short code
EC FimF41a gene Islt Ql NAA+probe
Synonyms
EC FimF41a gene Islt Ql NAA+probe
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
probe-amp-tar
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you have a family history of cancers like colorectal, gastric, or pancreatic cancer, or if you meet other genetic risk criteria. It’s also used in certain hereditary cancer syndromes.

What to Expect Before the Test

No special preparation is needed. You’ll provide a blood sample, similar to other blood tests. Results are typically available within 1–2 weeks, depending on lab processing.

What the Results Mean

Results may show normal gene function, a mutation present, or unclear findings. A mutation could increase cancer risk, prompting closer monitoring or preventive strategies.

Common Missteps & Clarifications

This test focuses only on *Epsilon-Cadherin* mutations. It does not screen for all cancer-related genes and is not a routine cancer screening test.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: *Epsilon-Cadherin* mutations are rare but linked to familial adenomatous polyposis (FAP) variants or other rare syndromes. Early detection may influence surveillance or surgical recommendations.

Short name

Epsilon-Cadherin Gene Test

Frequently asked questions

Will this test show all types of cancer?
No. This test specifically checks for mutations in the *Epsilon-Cadherin* gene. Other cancer-related genes may require separate testing.
How long does it take to get results?
Results typically arrive within 1–2 weeks, but timelines vary by lab. Your provider will discuss this with you during follow-up.
Does this test replace standard cancer screenings?
No. This is a targeted genetic test for specific mutations. Standard screenings (e.g., colonoscopies, mammograms) remain essential for early cancer detection.
  1. 1
    MedlinePlus — Laboratory TestsSource
  2. 2
    Lab Tests OnlineSource
  3. 3
    Mayo Clinic — Tests & ProceduresSource

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy